CHRSCoherus Oncology, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $42M
- 60% YoY
- Operating margin
- -429.5%
- 43% YoY
- EBITDA
- −$180M
- 9.2% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$9M net debt
- AI in 10-K
- —
Red flags 2 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-82% of net incomeCash flow under 80% of net income
- Dilutive SBCFired40% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $327M | $211M | $1M | $26M | $42M | 60% |
| Operating income | −$264M | −$257M | −$216M | −$200M | −$181M | 9.3% |
| Net income | −$287M | −$292M | −$238M | $29M | $168M | 489% |
| Operating cash flow | −$37M | −$241M | −$175M | −$20M | −$139M | 578% |
| Capex | $1M | $2M | $286K | — | — | |
| Stock-based comp | $51M | $51M | $43M | $28M | $17M | 39% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $3M | 18 | — |
| FY2024 | $5M | $2M | 17 | — |
| FY2023 | $6M | $2M | 42 | — |